Details of the Drug Combination

General Information of Drug Combination (ID: DC3H2SN)

Drug Combination Name
Degarelix ARN-509
Indication
Disease Entry Status REF
Prostate Cancer Phase 2 [1]
Component Drugs Degarelix   DM3O8QY ARN-509   DMT81LZ
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Degarelix
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Approved [2]
Degarelix Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Gonadotropin-releasing hormone receptor (GNRHR) TT8R70G GNRHR_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Indication(s) of ARN-509
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Approved [3]
Prostate cancer 2C82.0 Phase 3 [4]
ARN-509 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Androgen receptor (AR) TTS64P2 ANDR_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
ARN-509 Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [6]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03080116) Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5585).
3 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
4 ClinicalTrials.gov (NCT01946204) A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer. U.S. National Institutes of Health.
5 Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II. J Med Chem. 2005 Jul 28;48(15):4851-60.
6 Apalutamide: first global approval. Drugs. 2018 Apr;78(6):699-705.